Nesta report features Cambridge Cognition

RNS Number : 2914C

Cambridge Cognition Holdings PLC

14 March 2014

 



Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Nesta report features Cambridge Cognition

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, welcomes the publication of The Nesta report where the Company features heavily, in regards to the new wave of medtech companies leading the UK's Silicon Valley revolution.

Nesta is the UK's innovation foundation, an independent charity, helping people and organisations bring ideas to life. In this report, Silicon Valley Comes to the UK (SVC2UK) and Nesta present an overview of innovative companies and how they will play into changes in the broader healthcare sector.

Cambridge Cognition is listed as one of the companies that manages the complex relationships between doctors, researchers and government policy. The Company also features due to the technology being used in several hundred clinical research sites in over 50 countries, testing patients' cognitive function to enable faster diagnosis, as well as being used in clinical trials. Connectivity has enabled real-time data streaming and visualisation allowing the Company technology to check patient responses against expectations, measure, monitor and recommended procedural modifications (e.g. to accelerate patient enrolment) for research and clinical institutions even as the trial is progressing - reducing costs and improving data quality. Cambridge Cognition's research team use this information to test the underlying software, providing phased update of reference standards for assessing patients. 

For the full report please visit:

http://www.nesta.org.uk/sites/default/files/refilling_the_innovators_prescription.pdf 

Andy Blackwell, Chief Scientific Officer, comments: "The report brings together all the relevant issues facing provision of healthcare in the UK and the inclusion of Cambridge Cognition is a testament to the quality of our products and the years of research that has lead us to be recognised in this prestigious report for our ability to identify and therefore treat cognitive disease earlier."

Enquiries:

Cambridge Cognition Holdings plc	www.cambridgecognition.com
Nick Kerton, Chief Executive Officer	Tel: [phone]
Nick Walters, Chief Financial Officer
finnCap Ltd (Nomad and Broker)	Tel: [phone]
Matthew Robinson/Henrik Persson/Simon Hicks	(Corporate Finance)
Simon Starr	(Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products.  The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families. 

 

END

 

 

NRAJJMPTMBJBBTI